# Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone

> **NCT03742063** · — · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 190 (actual)

## Conditions studied

- Clinical Response
- Histopathological Response
- Prognosis

## Interventions

- **DRUG:** first-line chemotherapy

## Key facts

- **NCT ID:** NCT03742063
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2017-12-31
- **Final completion:** 2018-10-30
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2019-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742063, "Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03742063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*